Akamai EdgeSuite Selected by World Leader in Healthcare, Novartis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 6, 2001
Novartis relies on Akamai EdgeSuite(SM) to power its breakthrough
leukemia drug family of websites, Gleevec.com, Glivec.com, and
Akamai Technologies, Inc., (Nasdaq: AKAM), the leading provider of distributed application and content delivery services, today announced Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG, a world leader in healthcare, has chosen Akamai's next-generation content delivery service, EdgeSuite, to deliver Novartis' websites designed to provide patients and healthcare providers with information on Gleevec, a new FDA-approved treatment for patients with chronic myeloid leukemia (CML). EdgeSuite, a dynamic platform of managed "edge" services, allows global enterprises like Novartis to improve Web performance and reliability while minimizing the complexities associated with managing a uniform Web infrastructure.
To support public interest following the launch of Gleevec, Novartis sought an edge delivery solution for the drug's informational websites that could guarantee uptime, provide unparalleled experiences for its customers, and protect its billion-dollar brand. In addition, Novartis required a scalable, cost-effective solution that could simplify the intricacy and cost of deploying and operating the Gleevec sites' web infrastructure. Able to address these and other web operations needs, EdgeSuite was implemented by Novartis to provide whole site delivery on Gleevec.com, Glivec.com, and Novartisoncology.com.
"The availability and reliability of our product websites are absolutely critical to our business and to maintaining effective interaction with our customers and stakeholders," said Sam Rini, executive director, eBusiness marketing, Novartis. "The two-fold advantage of EdgeSuite is the measurable performance increase and the ability to support unexpected volumes of traffic."
Approved by the FDA on May 10th for the treatment of patients with CML in blast crisis, accelerated phase or chronic phase after failure of interferon-alpha therapy, Gleevec's breakthrough abilities, combined with its speed of development and approval - it was the FDA's fastest-approved cancer drug - drew massive amounts of publicity and an enormous amount of traffic to its web properties. Built upon Akamai's distributed network of close to 10,000 servers, EdgeSuite's unrivaled scalability allowed Novartis to easily meet significant end-user requests for 100% of its website content, and reduced Novartis' need for costly infrastructure capacity planning and peak crowd provisioning, enabling the Company to focus on its critical drug launch. During and after the launch, EdgeSuite continues to deliver maximum uptime and superior performance for Novartis.
"The increasing adoption of EdgeSuite by enterprises like Novartis is testament to the depth of our technology and the breadth of our network platform, as well as to the acceptance of EdgeSuite as a complete solution to the mission-critical Web infrastructure needs of our customers," said Mike Campbell, vice president, sales, Akamai. "We're pleased to have this unique opportunity to support Novartis' landmark leukemia treatment launch, and to complement its efforts to deliver vital Gleevec information to patients around the world as quickly as possible and with maximum performance."
A comprehensive offering, Akamai EdgeSuite enables whole website delivery, dynamic page assembly, streaming media delivery, geo-location and personalization, local and global load balancing, and business intelligence. As businesses seek to cost-effectively manage vital Web infrastructure at the Internet's edge, EdgeSuite provides enterprises with unmatched scalability by reducing the need for infrastructure capacity planning; ease of integration for fast deployment and greatly reduced staffing costs; and a pay-as-you-use pricing structure that allows companies to deploy their Web operations without a lot of upfront capital expenditure.
Novartis AG (NYSE: NVS) is a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health. In 2000, the Group's ongoing businesses achieved sales of CHF 29.1 billion (USD 17.2 billion) and a net income of CHF 6.5 billion (USD 3.9 billion). The Group invested approximately CHF 4.0 billion (USD 2.4 billion) in R&D. Headquartered in Basel, Switzerland, Novartis employs about 69,000 people and operates in over 140 countries around the world. For further information please consult http://www.novartis.com.
Akamai is the leading provider of distributed application and content delivery services, enabling companies to reduce the complexity and cost of deploying and operating a uniform Web infrastructure. Akamai's intelligent edge platform for content, streaming media, and application delivery comprises more than 9,700 servers within 650 networks in more than 56 countries. With headquarters in Cambridge, Massachusetts, Akamai provides services to more than 1,400 companies worldwide.
Akamai Statement Under the Private Securities Litigation Reform Act
The release contains information about future expectations, plans and prospects of Akamai's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, the dependence on Akamai's Internet content delivery service, a failure of its network infrastructure, the complexity of its service and the networks on which the service is deployed, the failure to obtain access to transmission capacity and other factors that are discussed in the Company's Annual Report on Form 10-K and other documents periodically filed with the SEC.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 2001|
|Previous Article:||Total Access Outside Plant Access Terminal Adds Flexibility to Remote Deployments.|
|Next Article:||AIB Announces New Eurozone Currency Charges.|